A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 266 participants.
Also called NCT05188417
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 266 participants
- Sponsor
- GrandPharma (China) Co., Ltd.
- Registry
-
NCT05188417
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05188417. Randomized; quadruple masking; primary purpose treatment. Start 2021-12-09 (actual); primary completion 2023-03-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study Evaluating the Safety and Efficacy of Tirofiban in Combination With Alteplase in Acute Ischemic Stroke
- Acronym
- RESET
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Tirofiban 0.05 MG/ML
- Intervention (Drug)
- 0.9% sodium chloride solution
- Lead sponsor
- GrandPharma (China) Co., Ltd.
Record details
- Record id
cardio:ct-nct05188417- Content hash
924a11b08c7af95750d0810b88d7bf36defddf72492447dfb0814d2350e5597a